284 related articles for article (PubMed ID: 36696754)
1. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
[TBL] [Abstract][Full Text] [Related]
4. Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain.
Lee B; Ko JH; Lee KH; Kim YC; Song YG; Park YS; Baek YJ; Ahn JY; Choi JY; Song KH; Kim ES; Bae S; Kim SH; Jeong HW; Kim SW; Kwon KT; Kim SH; Jeong H; Kim B; Kim SS; Choi WS; Peck KR; Kang ES
Microbiol Spectr; 2022 Dec; 10(6):e0266922. PubMed ID: 36250875
[TBL] [Abstract][Full Text] [Related]
5. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
[TBL] [Abstract][Full Text] [Related]
6. Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern.
Santos da Silva E; Servais JY; Kohnen M; Arendt V; Staub T; The Con-Vince Consortium ; The CoVaLux Consortium ; Krüger R; Fagherazzi G; Wilmes P; Hübschen JM; Ollert M; Perez-Bercoff D; Seguin-Devaux C
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834413
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test.
Lynch KL; Zhou S; Kaul R; Walker R; Wu AH
Clin Chem; 2022 May; 68(5):702-712. PubMed ID: 35018416
[TBL] [Abstract][Full Text] [Related]
9. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
[TBL] [Abstract][Full Text] [Related]
11. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
Bošnjak B; Stein SC; Willenzon S; Cordes AK; Puppe W; Bernhardt G; Ravens I; Ritter C; Schultze-Florey CR; Gödecke N; Martens J; Kleine-Weber H; Hoffmann M; Cossmann A; Yilmaz M; Pink I; Hoeper MM; Behrens GMN; Pöhlmann S; Blasczyk R; Schulz TF; Förster R
Cell Mol Immunol; 2021 Apr; 18(4):936-944. PubMed ID: 33139905
[TBL] [Abstract][Full Text] [Related]
12. Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2.
Hoffman T; Kolstad L; Akaberi D; Järhult JD; Rönnberg B; Lundkvist Å
Viruses; 2023 May; 15(6):. PubMed ID: 37376580
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
Pezzati L; Milazzo L; Carrozzo G; Kullmann C; Oreni L; Beltrami M; Caronni S; Lai A; Caberlotto L; Ottomano C; Antinori S; Ridolfo AL
J Infect Chemother; 2023 Jun; 29(6):624-627. PubMed ID: 36914095
[TBL] [Abstract][Full Text] [Related]
14. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.
Adams O; Andrée M; Hermsen D; Lübke N; Timm J; Schaal H; Müller L
J Virol Methods; 2022 Sep; 307():114569. PubMed ID: 35724697
[TBL] [Abstract][Full Text] [Related]
15. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
Luo YR; Yun C; Chakraborty I; Wu AHB; Lynch KL
J Clin Microbiol; 2021 Jun; 59(7):e0019321. PubMed ID: 33827900
[TBL] [Abstract][Full Text] [Related]
16. Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273.
Krüttgen A; Lauen M; Klingel H; Imöhl M; Kleines M
J Virol Methods; 2022 Jan; 299():114297. PubMed ID: 34563583
[TBL] [Abstract][Full Text] [Related]
17. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2.
Watanabe Y; Matsuba I; Watanabe K; Kunishima T; Takechi Y; Takuma T; Araki Y; Hirotsu N; Sakai H; Oikawa R; Danno H; Fukuda M; Futagami S; Wada K; Yamamoto H; Itoh F; Oda I; Hatori Y; Degawa H
J Clin Lab Anal; 2022 Jul; 36(7):e24545. PubMed ID: 35678628
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.5 variants.
Lee B; Ko JH; Kim YC; Baek JY; Park YS; Song KH; Kim ES; Lee KH; Song YG; Ahn JY; Choi JY; Choi WS; Bae S; Kim SH; Jeong HW; Lee YJ; Kim HJ; Choi JY; Kim B; Kim SW; Kwon KT; Peck KR; Kang ES
J Med Virol; 2023 Dec; 95(12):e29329. PubMed ID: 38140877
[TBL] [Abstract][Full Text] [Related]
20. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]